Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Vaxcyte, Inc. (PCVX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/04/2023 8-K Entry into a Material Definitive Agreement  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
10/02/2023 144 Form 144 - Report of proposed sale of securities:
10/02/2023 144 Form 144 - Report of proposed sale of securities:
10/02/2023 144 Form 144 - Report of proposed sale of securities:
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Quarterly results
Docs: "Vaxcyte Reports Second Quarter 2023 Financial Results and Provides Business Update -- Advanced Ongoing VAX-24 Phase 2 Infant Study to Second Stage, Dosing First New Participants in July 2023; Topline Data from Primary Immunization Series Expected by 2025 -- -- Completed Phase 2 VAX-24 Adult Program for the Prevention of Invasive Pneumococcal Disease ; Topline Phase 3 Data Expected in 2025 -- -- VAX-31 Adult Investigational New Drug Application Clearance Expected in Fourth Quarter of 2023; Topline Phase 1/2 Data Expected in 2024 -- -- $1.4 Billion in Cash, Cash Equivalents and Investments as of June 30, 2023, Including Net Proceeds of $545.3 Million from April Public Offering -- SAN CARLOS, Calif., August 8, 2023 – Vaxcyte, Inc. , a clinical-stage vaccine innovation company engineering high..."
05/08/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/08/2023 8-K Quarterly results
Docs: "Vaxcyte Reports First Quarter 2023 Financial Results and Provides Business Update -- Positive Data from VAX-24 Phase 2 Study in Adults Aged 65 and Older Demonstrated Robust Immune Responses Across all 24 Serotypes at all Doses, Confirming Prior Phase 2 Results in Adults Aged 50-64 -- -- Full Six-Month Safety Data from Both Adult Studies Demonstrated VAX-24 Safety and Tolerability Results Similar to PCV20 at All Doses Studied -- -- Dosed First Participants in Infant Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease -- -- VAX-31 Progressing with Adult Investigational New Drug Application Submission and Subsequent Clearance Announcement Expected in Second Half 2023 and Topline Phase 1/2 Data in 2024 -- -- $949.9 Million in Cash, Cash Equivalents and Investmen..."
04/28/2023 ARS Form ARS - Annual Report to Security Holders:
04/28/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/28/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/20/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
04/19/2023 8-K Quarterly results
04/17/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
04/17/2023 8-K Quarterly results
03/06/2023 8-K Entry into a Material Definitive Agreement  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
02/27/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
02/27/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Amendment No. 1 to Sales Agreement, by and between Vaxcyte, Inc. and Jefferies LLC",
"Opinion of Cooley LLP"
02/27/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
02/27/2023 10-K Annual Report for the period ended December 31, 2022
02/27/2023 8-K Quarterly results
Docs: "Vaxcyte Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update -- Company Received U.S. Food and Drug Administration Clearance of VAX-24 Infant Investigational New Drug Application and Expects to Initiate Phase 2 Study in Second Quarter 2023 -- -- Topline Safety, Tolerability and Immunogenicity Results from VAX-24 Phase 2 Study in Adults 65 and Older on Track for Second Quarter 2023 -- -- Positive Topline Results from VAX-24 Phase 1/2 Proof-of-Concept Study in Adults Aged 18-64 Indicate Potential Best-in-Class Profile and Validate Company’s Carrier-Sparing Approach -- -- VAX-31 Progressing with Adult IND Application Expected in Second Half 2023 and Topline Phase 1/2 Data in 2024 -- -- Successfully Raised Approximately $805 Million in Gross Proceeds in Two ..."
02/14/2023 SC 13G/A RA CAPITAL MANAGEMENT, L.P. reports a 10% stake in VAXCYTE, INC.
02/10/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/10/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/10/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/09/2023 SC 13G/A FMR LLC reports a 12.9% stake in VAXCYTE INC
02/09/2023 SC 13G/A VANGUARD GROUP INC reports a 8.4% stake in Vaxcyte Inc.
12/22/2022 S-3ASR Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers:
12/20/2022 8-K Quarterly results
12/12/2022 8-K Quarterly results
11/07/2022 8-K Quarterly results
Docs: "Vaxcyte Reports Third Quarter 2022 Financial Results and Provides Business Update -- Vaxcyte Reported Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64 -- --Phase 1/2 Study Met Safety, Tolerability and Immunogenicity Objectives; Findings Indicate a Potential Best-in-Class Profile for VAX-24 -- -- Company Advancing VAX-24 in Adult and Pediatric Populations with Submission of Infant Investigational New Drug Application and Study Initiation Expected in First Half of 2023 -- -- $366.2 Million in Cash, Cash Equivalents and Investments as of September 30, 2022, Excluding Net Proceeds of Approximately $650.7 Million from Recent Public Offe..."
11/07/2022 10-Q Quarterly Report for the period ended September 30, 2022
10/26/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
10/26/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy